This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): E7300
Description: ZYC300 is an encapsulated plasmid that contains the tumor antigen cytochrome P450 1B1 (CYP1B1). ZYC300 stimulates the body's T cells to attack cells that express CYP1B1. CYP1B1 is a tumor-specific protein that is found expressed in nearly every major cancer but significantly limited in normal tissue.
Deal Structure: ZYC300 was originally developed by MGI Pharma.
In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI Pharma for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.
Additional information available to subscribers only: